{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:33:21Z","timestamp":1789907601744,"version":"4.0.1"},"reference-count":30,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tisagenlecleucel (tisa\u2010cel) is a second\u2010generation autologous CD19\u2010targeted chimeric antigen receptor (CAR) T\u2010cell therapy approved for relapsed\/refractory (R\/R) large B\u2010cell lymphoma (LBCL). The approval was based on the results of phase II JULIET trial, with a best overall response rate (ORR) and complete response (CR) rate in infused patients of 52% and 40%, respectively. We report outcomes with tisa\u2010cel in the standard\u2010of\u2010care (SOC) setting for R\/R LBCL. Data from all patients with R\/R LBCL who underwent leukapheresis from December 2018 until June 2020 with the intent to receive SOC tisa\u2010cel were retrospectively collected at 10 Spanish institutions. Toxicities were graded according to ASTCT criteria and responses were assessed as per Lugano 2014 classification. Of 91 patients who underwent leukapheresis, 75 (82%) received tisa\u2010cel therapy. Grade 3 or higher cytokine release syndrome and neurotoxicity occurred in 5% and 1%, respectively; non\u2010relapse mortality was 4%. Among the infused patients, best ORR and CR were 60% and 32%, respectively, with a median duration of response of 8.9\u00a0months. With a median follow\u2010up of 14.1\u00a0months from CAR T\u2010cell infusion, median progression\u2010free survival and overall survival were 3\u00a0months and 10.7\u00a0months, respectively. At 12\u00a0months, patients in CR at first disease evaluation had a PFS of 87% and OS of 93%. Patients with an elevated lactate dehydrogenase showed a shorter PFS and OS on multivariate analysis. Treatment with tisa\u2010cel for patients with relapsed\/refractory LBCL in a European SOC setting showed a manageable safety profile and durable complete responses.<\/jats:p>","DOI":"10.1002\/cam4.3881","type":"journal-article","created":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T09:05:27Z","timestamp":1619859927000},"page":"3214-3223","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":129,"title":["Real\u2010world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B\u2010cell lymphoma"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0805-9288","authenticated-orcid":false,"given":"Gloria","family":"Iacoboni","sequence":"first","affiliation":[{"name":"Department of Hematology University Hospital Vall d'Hebron Barcelona Spain"},{"name":"Department of Medicine Universitat Aut\u00f2noma de Barcelona Bellaterra Spain"},{"name":"Experimental Hematology Vall d\u2019Hebron Institute of Oncology (VHIO) Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Villacampa","sequence":"additional","affiliation":[{"name":"Oncology Data Science Vall d\u2019Hebron Institute of Oncology (VHIO) Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Martinez\u2010Cibrian","sequence":"additional","affiliation":[{"name":"Department of Hematology University Hospital Virgen del Rocio Sevilla Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Bail\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Hematology Hospital General Universitario Gregorio Mara\u00f1\u00f3n Madrid Spain"},{"name":"Gregorio Mara\u00f1\u00f3n Health Research Institute (IiSGM) Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Lopez Corral","sequence":"additional","affiliation":[{"name":"Hematology Department Hospital Cl\u00ednico Universitario de Salamanca IBSAL, CIBERONC Salamanca Spain"},{"name":"Centro de Investigaci\u00f3n del C\u00e1ncer\u2010IBMCC Salamanca Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Hematology Department Hospital 12 de Octubre Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Guerreiro","sequence":"additional","affiliation":[{"name":"Department of Hematology Hospital La Fe Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Carolina","family":"Caballero","sequence":"additional","affiliation":[{"name":"Hematology Department Hospital de la Santa Creu i Sant Pau Barcelona Spain"},{"name":"Josep Carreras Leukaemia Research Institute Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Mussetti","sequence":"additional","affiliation":[{"name":"Hematology Department Institut Catala d'Oncologia Hospital Duran i Reynals, L'Hospitalet De Llobregat Spain"},{"name":"Institut d'Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) L'Hospitalet De Llobregat Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7168-6538","authenticated-orcid":false,"given":"Juan\u2010Manuel","family":"Sancho","sequence":"additional","affiliation":[{"name":"Hematology Department ICO\u2010IJC Hospital Germans Trias i Pujol Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Hernani","sequence":"additional","affiliation":[{"name":"Department of Hematology Hospital Cl\u00ednico Universitario de Valencia Valencia Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria INCLIVA Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Abrisqueta","sequence":"additional","affiliation":[{"name":"Department of Hematology University Hospital Vall d'Hebron Barcelona Spain"},{"name":"Department of Medicine Universitat Aut\u00f2noma de Barcelona Bellaterra Spain"},{"name":"Experimental Hematology Vall d\u2019Hebron Institute of Oncology (VHIO) Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Solano","sequence":"additional","affiliation":[{"name":"Department of Hematology Hospital Cl\u00ednico Universitario de Valencia Valencia Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria INCLIVA Valencia Spain"},{"name":"Department of Medicine University of Valencia Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"Hematology Department Institut Catala d'Oncologia Hospital Duran i Reynals, L'Hospitalet De Llobregat Spain"},{"name":"Institut d'Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) L'Hospitalet De Llobregat Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Briones","sequence":"additional","affiliation":[{"name":"Hematology Department Hospital de la Santa Creu i Sant Pau Barcelona Spain"},{"name":"Josep Carreras Leukaemia Research Institute Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Martin Garcia\u2010Sancho","sequence":"additional","affiliation":[{"name":"Hematology Department Hospital Cl\u00ednico Universitario de Salamanca IBSAL, CIBERONC Salamanca Spain"},{"name":"Centro de Investigaci\u00f3n del C\u00e1ncer\u2010IBMCC Salamanca Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Hematology Hospital General Universitario Gregorio Mara\u00f1\u00f3n Madrid Spain"},{"name":"Gregorio Mara\u00f1\u00f3n Health Research Institute (IiSGM) Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luis","family":"Reguera\u2010Ortega","sequence":"additional","affiliation":[{"name":"Department of Hematology University Hospital Virgen del Rocio Sevilla Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7076-7969","authenticated-orcid":false,"given":"Pere","family":"Barba","sequence":"additional","affiliation":[{"name":"Department of Hematology University Hospital Vall d'Hebron Barcelona Spain"},{"name":"Department of Medicine Universitat Aut\u00f2noma de Barcelona Bellaterra Spain"},{"name":"Experimental Hematology Vall d\u2019Hebron Institute of Oncology (VHIO) Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"GETH, GELTAMO Spanish Groups","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,5]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.213"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13440"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02104"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02103"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25951"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003001"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003092"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-020-01521-5"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_2_10_21_1","unstructured":"US Department of Health and Human Services NIoH National Cancer Institute.Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. November2017."},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05094.x"},{"key":"e_1_2_10_23_1","unstructured":"R T.Regression shrinkage and selection via the lasso. J Roy Statist Soc Ser B.1996."},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.110.957951"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001304"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000952"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127490"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124177"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002394"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001900"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.3881","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.3881","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.3881","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T02:44:57Z","timestamp":1693622697000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.3881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1002\/cam4.3881"],"URL":"https:\/\/doi.org\/10.1002\/cam4.3881","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"2020-12-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}